Did Pantheon Get Enough in Its Buyout?
Pantheon shares saw a huge gain on Monday following the announcement that the company will be acquired by Thermo Fisher Scientific.
All Work
Chris Lange
Why Analysts Are Growing Bullish on Salesforce Ahead of Earnings
Salesforce.com is scheduled to release its most recently quarterly financial results after the markets close on Thursday. And analysts are already keying in on the stock, mostly taking a positive stance and putting in…
The Case for Cybersecurity Stocks After the WannaCry Virus
Starting last Friday, a massive cyberattack took place across the globe that locked up over 200,000 computers in 150 countries. The ransomware virus is known as WannaCry.
Why Ionis Pharma Is Sinking Despite Solid Late-Stage Results
Ionis Pharmaceuticals saw its shares pullback on Monday morning after results were released from its late-stage trial for the treatment of familial amyloid polyneuropathy.
BlackLine Files for Secondary Offering
Blackline has filed with the U.S. Securities and Exchange Commission (SEC) regarding its secondary offering.
Wal-Mart, Cisco and More Earnings Coming This Week
24/7 Wall St. has put together a preview of Alibaba, Cisco, Wal-Mart and a few other major companies scheduled to report their quarterly results this coming week.
What Analysts Are Saying About Disney After Earnings
Disney reported its most recent quarterly results on Tuesday. This report was not as strong as analysts were expecting, and investors sent shares lower, if only slightly.
How Analysts View Snap After Earnings
Snap saw its shares absolutely crumble following its first-quarter earnings report late on Wednesday. Analysts nearly across the board cut their targets, taking a little more air out of the stock in the longer…
How Ebola Stocks Are Responding After the Outbreak in the Congo
The WHO has confirmed a new outbreak of the Ebola virus in the Democratic Republic of Congo. A few of the Ebola-related stocks are responding.
Why Merrill Lynch Sees Apple Rising to $180!
Apple shares hit another all-time high in Friday’s session following one impressive upgrade from Merrill Lynch.
Ziopharm Prices Secondary Offering
Ziopharm Oncology saw its shares slide early on Friday after the company announced the pricing of its secondary offering.
CyberArk Sinks Following Missed Guidance
CyberArk Software shares fell early Friday in the wake of its mixed first-quarter financial results.
G1 Therapeutics Announces Potential Pricing for IPO
G1 Therapeutics expects to offer more than 6 million shares in the range of $15 to $17 apiece in an initial public offering valued up to around $122 million.
Nordstrom Sinks Despite Beating Earnings
Nordstrom, Inc. (NYSE: JWN) reported its fiscal first-quarter financial results after the markets closed on Thursday. The company said that it had $0.43 in earnings per share (EPS) and $3.3 billion in revenue, versus…
Thursday’s Biggest Winners and Losers in the S&P 500
May 11, 2017: The S&P 500 closed lower 0.2% on the day at 2,394.47. Separately the DJIA closed lower 0.1% at 20,919.76. The Nasdaq was also lower 0.2% closing at 6,115.96.
Why Merrill Lynch Jumped on the Caterpillar Upgrade Brigade
Caterpillar has had a positive year so far, with its shares last seen trading up about 10%. Earnings were far better than expected and many analysts have raised their price targets and ratings.
Why Analysts Are Taking a Mixed Stance on Symantec After Earnings
When Symantec reported its most recent quarterly results late on Wednesday, the results were not close to what analysts expected and shares behaved accordingly.
Why Sangamo Therapeutics Is Surging
Sangamo Therapeutics saw its shares skyrocket early on Thursday after a critical business update.
US Foods Gears Up for Secondary Offering
US Foods has filed with the U.S. Securities and Exchange Commission for a secondary offering valued at up to more than $1 billion.
Are Macy’s Digital Hopes Too Little Too Late?
Macy’s reported disappointing fiscal first-quarter financial results before the markets opened on Thursday.